Test Your Skills: Medullary Thyroid Cancer

CE / CME

Test Your Skills: Understanding the Current Biomarker Landscape for Patients With Medullary Thyroid Cancer

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Released: September 17, 2024

Expiration: September 16, 2025

Joseph H. Friedman
Joseph H. Friedman, MD
Saad A Khan
Saad A Khan, MD
Diane K. Newman
Diane K. Newman, DNP, ANP-BC, FAAN
Steven Christopher Smith
Steven Christopher Smith, MD, PhD
Laura J. Tafe
Laura J. Tafe, MD

Activity

Progress
1 2
Course Completed

History
A 34-year-old male patient was diagnosed with MTC with extensive lymphadenopathy. He underwent a total thyroidectomy, central neck dissection, mediastinal node removal, and modified radical neck dissection (MRND) level II-V. Surgical pathology was consistent with pT3aN1b MTC. Histologic examination of the thyroid specimens revealed no signs of papillary thyroid cancer.

After thyroidectomy, germline testing was performed with paired normal samples and found to be negative for RET mutations.

Current Presentation
After 12 months, his serum calcitonin is 650 pg/mL and CEA is 120 ng/mL. MRI of the patient’s abdomen revealed multiple hepatic lesions suspicious for metastasis.

The patient was referred to you for possible treatment options for his recurrent metastatic MTC

Based on this information, what would you recommend next for this patient?